PPF ("PMG Partners Funds") - PMG Global Biotech Fund - R

The aim of the fund is to achieve mid- and long-term capital appreciation by investing in the biotech sector. Biotech innovation drives the development of first-in-class and best-in-class of drugs which benefits directly to patients and often leads to financial gains through M&A's or stock appreciation. The strategy of the fund is to cover small- and mid-cap companies broadly while capturing a steady Performance through large-cap investment. The fund invests in listed biotech stocks in major stock exchanges worldwide.
The fund uses a systemic approach to map investible companies based on the fund's proprietary criteria, which reflect on company-specific value inflection points, as well as sector and market trends. A mix of fundamental, quantitative and qualitative analyses is employed to select investible companies. The fund works closely with its advisors to reach best performance outcomes. The NASDAQ Biotechnology Index serves as the benchmark.

NAV/unit
USD
YTD

Lowest/Highest NAV
/
/
NAV
USD
in millions
Fund management / Fund administrator
MultiConcept Fund Management S.A.
Custodian
Credit Suisse (Luxembourg) S.A.
Investment Manager
PMG Investment Solutions AG
Auditor
PricewaterhouseCoopers
Supervisory authority
CSSF
Domicile
Luxembourg
Fiscal year end
31. December
Launch date
September 30th 2015
Valuation frequency
daily
Distribution policy
accumulating
Publication medium
www.swissfunddata.ch, www.pmg.swiss
ISIN
LU1230343250
Valor
28164379
Bloomberg
PPFCGRU LX
Subscription category
shares and amount
Minimal initial subscription
1
Reference currency
USD
Cut-off time for subscription
17:00
Distribution in Switzerland
yes
Distribution in Germany
yes
Subscription fee maximum
1.00%
Redemption fee maximum
none
TER excluding performance fee
1.90%
TER including performance fee
1.90%
TER date
December 31st 2021
Management fee applied
1.35%
German tax category
transparent
Presentation
Fund prospectus
KIID
Annual report
Semi-annual report
Factsheets
Management commentary
German Investor Fund Tax Information

Description

The aim of the fund is to achieve mid- and long-term capital appreciation by investing in the biotech sector. Biotech innovation drives the development of first-in-class and best-in-class of drugs which benefits directly to patients and often leads to financial gains through M&A's or stock appreciation. The strategy of the fund is to cover small- and mid-cap companies broadly while capturing a steady Performance through large-cap investment. The fund invests in listed biotech stocks in major stock exchanges worldwide.
The fund uses a systemic approach to map investible companies based on the fund's proprietary criteria, which reflect on company-specific value inflection points, as well as sector and market trends. A mix of fundamental, quantitative and qualitative analyses is employed to select investible companies. The fund works closely with its advisors to reach best performance outcomes. The NASDAQ Biotechnology Index serves as the benchmark.

Fund Characteristics

Fund management / Fund administrator
MultiConcept Fund Management S.A.
Custodian
Credit Suisse (Luxembourg) S.A.
Investment Manager
PMG Investment Solutions AG
Auditor
PricewaterhouseCoopers
Supervisory authority
CSSF
Domicile
Luxembourg
Fiscal year end
31. December
Launch date
September 30th 2015
Valuation frequency
daily
Distribution policy
accumulating
Publication medium
www.swissfunddata.ch, www.pmg.swiss
ISIN
LU1230343250
Valor
28164379
Bloomberg
PPFCGRU LX
Subscription category
shares and amount
Minimal initial subscription
1
Reference currency
USD
Cut-off time for subscription
17:00
Distribution in Switzerland
yes
Distribution in Germany
yes
Subscription fee maximum
1.00%
Redemption fee maximum
none
TER excluding performance fee
1.90%
TER including performance fee
1.90%
TER date
December 31st 2021
Management fee applied
1.35%
German tax category
transparent

Documents

Presentation
Fund prospectus
KIID
Annual report
Semi-annual report
Factsheet
Management commentary
German Investor Fund Tax Information